NCT05524935View on ClinicalTrials.gov

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Uveal MelanomaOcular Melanoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab Day 1 of each 21 day (3 week) cycle

DRUG

Olaparib

Olaparib by mouth days 1-21 of each 21 day (3 week) cycle

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER